{"name":"Alzheimer's Disease Expert Lab (ADEL), Inc.","slug":"alzheimer-s-disease-expert-lab-adel-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADEL-Y01 - healty participants","genericName":"ADEL-Y01 - healty participants","slug":"adel-y01-healty-participants","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ADEL-Y01 - healty participants","genericName":"ADEL-Y01 - healty participants","slug":"adel-y01-healty-participants","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNUTc4dEs0elh0dWFYNEZOaHBCSTY3enc5MHlNRTlvdFpWaWIyWkM5eVVkTUhEX0NnZ3RrUkRZTkpnejg0WGJpY2RYZU05ZTRLWldkWE9pN0IxU19TTjQtY2VnakRka2xZQ2V4dWR2UTVRdWI1a1JzN3VzMGVWVGVNWWJlSzRJZDVkZFFsT01JMUFhU21wbDNsaGpGX0k2NDZOR2Rn?oc=5","date":"2025-12-16","type":"deal","source":"BioWorld News","summary":"ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug - BioWorld News","headline":"ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQelBKSUQxeEwtc1N5STRJY2RuclJhd1hVMlRfbTdlVEJXbjFpREhFblE2S0hwdlZLUEhUM1R4a2FUQ3N2cHJpREUxeGwzS1BsMWZlWmZMNVVIX0xWWkpybUptWHhvSkJpeW5QcGxKRXNiSnQ1d0gwM3lsV1YwUm9pTE1yazVuOERBQ2s3TFFrVmZkWTNEY0tIREYzTGRGMkZpTmo0?oc=5","date":"2024-04-02","type":"pipeline","source":"BioWorld News","summary":"After amyloid beta, Adel seeks next big target for Alzheimer’s - BioWorld News","headline":"After amyloid beta, Adel seeks next big target for Alzheimer’s","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}